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Aqueous mistletoe extracts from the European mistletoe (Viscum album) contain mainly mistletoe lectins and viscotoxins as
cytotoxic compounds. Lipophilic triterpene acids, which do not occur in conventional mistletoe preparations, were solubilised
with β-cyclodextrins. The combination of an aqueous extract (viscum) and a triterpene-containing extract (TT) recreated a
whole mistletoe extract (viscumTT). These extracts were tested on rhabdomyosarcoma in vitro, ex vivo, and in vivo with regard
to anticancer eﬀects. Viscum and viscumTT inhibited cell proliferation and induced apoptosis eﬀectively in a dose-dependent
manner in vitro and ex vivo, whereas TT showed only moderate inhibitory eﬀects. viscumTT proved to be more eﬀective than
the single extracts and displayed a synergistic eﬀect in vitro and a stronger eﬀect in vivo. viscumTT induced apoptosis via the
extrinsic and intrinsic pathways, evidenced by the loss of mitochondrial membrane potential and activation of CASP8 and
CASP9. CASP10 inhibitor inhibited apoptosis eﬀectively, emphasising the importance of CASP10 in viscumTT-induced
apoptosis. Additionally, viscumTT changed the ratio of apoptosis-associated proteins by downregulation of antiapoptotic
proteins such as XIAP and BIRC5, thus shifting the balance towards apoptosis. viscumTT eﬀectively reduced tumour volume in
patient-derived xenografts in vivo and may be considered a promising substance for rhabdomyosarcoma therapy.
1. Introduction
Rhabdomyosarcoma (RMS) is the most common soft tissue
sarcoma in children and adolescents in Germany, accounting
for 3.1% of all paediatric tumours [1]. Alveolar RMS (ARMS)
is one of the two main histopathological subtypes and occurs
in approximately 25% of the cases [2–4]. ARMS is more com-
mon in adolescents and young adults and associated with
aggressive clinical behaviour and poor treatment response
and outcome [5]. Most of ARMS are characterised by the
balanced translocations t(2;13)(q35;q14) or t(1;13)(q36;14)
[6], resulting in the PAX3/FOXO1 (~55%) or PAX7/FOXO1
(~25%) fusion genes, respectively [7]. Despite aggressive
multimodal treatment regimes, the prognosis of fusion-
positive ARMS (65%) [8] and patients with metastatic disease
(<20%) [9] remains poor and has not changed in years [10],
highlighting the need for new therapy approaches.
Aqueous extracts of the European mistletoe (Viscum
album) are widely used in complementary cancer therapy
in German-speaking countries, despite their controversial
eﬃcacy since 1920. Viscum album contains a large variety
of biological active compounds including mistletoe lectins
(ML) [11], viscotoxins (VT) [12–14], triterpene acids
[15, 16], ﬂavonoids [17, 18], and polysaccharides [19, 20].
Commercially available mistletoe preparations are based on
aqueous extracts and contain mainly ML and VT as active
compounds. Mistletoe extracts have been shown to exert
cytotoxic eﬀects on acute leukaemia [21], multiple myeloma
[22], head and neck squamous cell carcinomas [23], and
bladder carcinoma [24] in vitro as well as acute leukaemia
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[25], breast cancer [26], malignant melanoma [27], and
pancreatic carcinoma [28] in vivo. Furthermore, there is
clinical evidence that Viscum album extracts prolong the
overall survival of patients with pancreatic cancer [29].
Lipophilic triterpene acids, such as oleanolic acid (OA)
and betulinic acid (BA), represent another group of
mistletoe-derived substances with known cytotoxic eﬀects.
Previous studies on neuroblastoma [30, 31], osteosarcoma
[32], acute leukaemia [33], breast cancer [34], and gastric
cancer [35] showed that OA and its derivatives inhibit cell
proliferation and induce apoptosis eﬀectively in vitro.
Moreover, in vivo experiments have shown cytotoxic
eﬀects of OA on osteosarcoma [36], gallbladder carcinoma
[37], hepatocellular carcinoma [38], and pancreatic carci-
noma [39]. Due to their low solubility, triterpene acids do
not occur in signiﬁcant amounts in commercial mistletoe
extracts [40]. Using cyclodextrins, it was possible to solu-
bilise triterpene acids and therefore to overcome their loss
in standardised aqueous extracts.
Previous studies showed the eﬃcacy of a combined mis-
tletoe extract produced by addition of solubilised triterpene
acids (TT) to aqueous mistletoe extracts (viscum), creating a
whole plant extract (viscumTT). This whole plant extract
eﬀectively induced apoptosis in acute myeloid and lympho-
blastic leukaemia [41, 42], Ewing-sarcoma [43], and osteo-
sarcoma [44] and inhibited tumour growth in murine
melanoma in vivo [45]. The aim of this study was to analyse
the eﬀect of the whole mistletoe extract, viscumTT, on rhab-
domyosarcoma in vitro, ex vivo, and in vivo.
2. Materials and Methods
2.1. Material and Reagents. RPMI 1640, penicillin, strepto-
mycin, trypsin (0.05%), and phosphate-buﬀered saline
(PBS) were purchased from Gibco®, Life Technologies
(Darmstadt, Germany). Foetal calf serum (FCS) was obtained
from Biochrom (Berlin, Germany). RIPA buﬀer, protease
inhibitors, molecular mass standards for SDS-PAGE, sodium
dodecyl sulfate (SDS), dimethyl sulfoxide (DMSO), 5,6,6-tet-
rachloro-1,1,3,3-tetraethylbenzimidazolcarbocyanine iodide
(JC-1), carbonyl cyanide 3-chlorophenylhydrazone (CCCP),
and propidium iodide (PI) were purchased from Sigma-
Aldrich (München, Germany). Tween, acrylamide, and
dithiotreitol (DTT) were purchased from Carl Roth GmbH
(Karlsruhe, Germany).
2.2. Viscum album Extracts. Viscum album extracts were
kindly provided by Birken AG (Niefern-Öschelbronn,
Germany) and prepared from Viscum album harvested
from apple trees (Malus domestica Borkh.) as previously
described [41, 42, 46]. Intact mistletoe lectin-I (A+B chain)
was quantiﬁed by ELISA in the viscum extract as described
before [47]. OA and BA were quantiﬁed in the TT extract
by gas chromatography-ﬂame ionisation detector (GC-FID)
and external calibration with OA as reference substance
[40]. Both extracts, viscum and TT, were reconstituted
in PBS to a ﬁnal concentration of 1μg/mL intact ML-I
and <1μg/mL VT in viscum and 4000μg/mL OA and
172μg/mL BA in TT (Table 1).
2.3. Cell Culture. Two human ARMS cell lines were used in
this study. RH-30 cells were obtained from the German
Collection of Microorganisms and Cell Cultures (DSMZ,
Braunschweig, Germany) and RMS-13 cells from the
American Type Culture Collection (ATCC, Manassas, VA,
USA). Both cell lines were maintained in RPMI 1640
medium with L-glutamine, supplemented with 10% heat-
inactivated FCS, 100U/mL penicillin, and 100μg/mL
streptomycin. For experimental settings, 2× 105/mLcellswere
seeded onto 6-well plateswith aﬁnal volumeof 2mL/well. Cell
numbers were adjusted to sizes of well plates according to
experimental settings. Cells were cultured 24h to allow cell
attachment, then viscum, TT, and viscumTT were added in
deﬁned concentrations for another 24 h.
2.4. Determination of Cell Proliferation and Measurement of
Early Cytotoxicity. Cell counts were determined with the
CASY® Cell Counter and Analyser System of Schärfe System
GmbH (Reutlingen, Germany). Alterations of cell prolifera-
tion were indicated as the percentage of untreated control
cells (100% viability). To rule out early cytotoxicity, lactate
dehydrogenase (LDH) release was measured after 2 h of incu-
bation with viscum, TT, and viscumTT using the Cytotoxicity
Detection Kit (Roche Diagnostics GmbH, Mannheim,
Germany) according to the manufacturer’s instructions.
2.5. Determination of Apoptosis. After 24 h incubation with
viscum, TT, and viscumTT in increasing concentrations, cells
were stained with APC-conjugated annexin V (BD Biosci-
ences, Heidelberg, Germany) and 1mg/mL PI as described
before [42]. Cells were analysed by ﬂow cytometry (FACSCa-
libur™, Becton Dickinson, Heidelberg, Germany), and results
were evaluated with FlowJo® Software (Tree Star, Inc.,
Ashland, USA).
2.6. Assessment of Mitochondrial Membrane Potential (ΔΨm).
Changes in mitochondrial membrane potential (ΔΨm) were
detected by JC-1 staining and ﬂow cytometry, according to
the manufacturer’s instructions. Subsequently, results were
evaluated with FlowJo Software. 50μM depolarising CCCP
was used as a reference control.
2.7. Determination of Caspase Activity. Activity of caspase-3
(CASP3), caspase-8 (CASP8), and caspase-9 (CASP9) was
measured using the Green Caspase Staining Kit (Promokine,
Heidelberg, Germany) according to the manufacturer’s pro-
tocol. Subsequently, cells were analysed by ﬂow cytometry
and results were evaluated with FlowJo Software.
2.8. Caspase Inhibitor Assays. Cells were pretreated for
one hour with 50–100μM caspase inhibitors, before 24 h
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incubation with viscum (2.5–5ng/mL) and viscumTT
(2.5–5ng/mL viscum+35–40μg/mL TT). DMSO was added
as a solvent control. Induction of apoptosis was determined
by annexin V/PI staining and ﬂow cytometry analysis as
described above. In this experimental setting, we used, in
addition to a pan-caspase inhibitor (Z-VAD-FMK), inhibi-
tors of CASP8 (Z-IETD-FMK), CASP9 (Z-LEHD-FMK),
and caspase-10 (CASP10; Z-AEVD-FMK) (R&D Systems,
Minneapolis, MN, USA).
2.9. Protein Extraction and Western Blot Analyses. Cells were
incubated with TT (OA 40μg/mL), viscum (ML 5ng/mL),
and viscumTT (OA 40μg/mL+ML 5ng/mL) for 24h. After
washing twice with PBS, cells were lysed for 30min in RIPA
buﬀer containing protease inhibitors. Protein lysates were
centrifuged at 14000 rpm for 5min at 4°C, then protein
concentrations were determined by Bradford Reagent (Bio-
Rad, München, Germany). Lysates (20–25μg protein/lane)
were separated by SDS-PAGE and transferred to nitrocellu-
lose membranes (Bio-Rad). Blots were incubated with
primary antibodies overnight at 4°C. After incubation with
HRP-conjugated secondary antibodies (Bio-Rad), protein
bands were visualized by ECL (Thermo Fisher Scientiﬁc,
Bonn, Germany) and Molecular Imager® ChemiDoc™
(Bio-Rad). The following primary antibodies were used:
β-actin (#A3854, Sigma-Aldrich), B-cell lymphoma 2
(BCL2; #2870, Cell Signaling Technology, CST, Danvers,
MA, USA), BCL2 like 1 (BCL2L1; #2764, CST), baculoviral
IAP repeat containing 5 (BIRC5; #2803, CST), myeloid cell
leukemia 1 (MCL1; sc-819, Santa Cruz Biotechnology, Santa
Cruz, CA, USA), poly(ADP-ribose) polymerase 1 (PARP1;
#9542, CST), and X-linked inhibitor of apoptosis protein
(XIAP; #610716, BD Biosciences).
2.10. Ex Vivo Cultured RMS Primary Cells. Tumour samples
were obtained as a treatment residue from three diﬀerent
patients with ARMS during routine surgical resection.
Tumour tissue was not explicitly collected for this study,
and diagnoses were conﬁrmed by histopathology by the
institute of pathology, Charité - Universitätsmedizin Berlin.
Immediately after surgical excision, tumour tissue from
patient no. 1 (11 years, female, recurrent disease), patient
no. 2 (12 years, male, primary disease), and patient no. 3
(13 years, female, primary disease) was cut into smaller pieces
and cultured as primary explants in RPMI 1640 base medium
with L-glutamine supplemented with 20% heat-inactivated
FCS and 1% penicillin/streptomycin solution. When cells
dissociated from the explant and formed a conﬂuent
monolayer culture, apoptosis induction was investigated. Ex
vivo cell cultures were used for experimental settings within
seven trypsinised passages. Because of slow or bad cell
growth, experiments could only be performed twice. For
analyses, cells were seeded into 12-well microtiter plates at
1.5 × 105–3×105 cells/well and incubated with increasing
concentrations of viscum, TT, and viscumTT as described
above. Subsequently, apoptosis was measured by annexin
V/PI assay. Further, JC-1 measurement was carried out with
cells from patient no. 1. In accordance with the Declaration
of Helsinki, written informed consent was obtained from
the patients and experiments were approved by the local
ethics committee of the Charité - Universitätsmedizin Berlin.
2.11. RMS Xenografts and Experimental Procedures. Patient-
derived RMS tissue was subcutaneously transplanted into
the left ﬂank of eight-week-old NMRI-nu/nu mice. The mice
were obtained from Charles River Laboratories (Sulzfeld,
Germany), housed in a pathogen-free facility under
pathogen-free conditions, and fed autoclaved standard diet
(Sniﬀ, Soest, Germany) with acidiﬁed drinking water ad
libitum. The tumour was propagated in vivo, and tumour
tissue from one in vivo passage was used for s.c. implanta-
tion in the inguinal region of seven (no. 1) or ﬁve (no. 2)
mice per treatment or control group. The same patient
material was used for ex vivo as well as in vivo experiments
(no. 1 ex vivo=no. 1 in vivo, no. 2 ex vivo=no. 2 in vivo).
Treatment with the test substances or controls started on
day 12 when tumours were palpable. Mice were treated with
viscum, TT, viscumTT, and cyclodextrins (control group)
intratumourally (i.t) and doxorubicin (Doxo) intravenously
(i.v.) in no. 1. In experiment no. 2, mice received viscumTT
i.t. and viscumTT and cyclodextrins i.v. The mice were
treated every two to three days in rising concentrations,
and each dose was given twice. The administered concentra-
tions were 40/60/80mg/kg OA (TT), 0.5/1.0/1.5μg/kg ML
(viscum), or a combination thereof (viscumTT). Body weight
was measured before each treatment, and mice were carefully
monitored for health and symptoms of toxicity. The animals
were sacriﬁced by cervical dislocation at the end of the
experiment or if the mice were moribund (tumour volu-
me> 1.2 cm3 or >10% body weight loss). The animal experi-
ments were carried out in accordance with the German
legislation on the care and use of laboratory animals and in
accordance with the United Kingdom Coordinating Com-
mittee on Cancer Research Guidelines for the Welfare of
animals in Experimental Neoplasia to minimise suﬀering.
Approval for the study was obtained from the Regional Oﬃce
for Health and Social Aﬀairs (LaGeSo, approval G-0030/15).
2.12. Statistics. All in vitro experiments were performed in
independent experiments at least three times, for which
means± standard error are displayed in bar graphs. Ex vivo
experiments were carried out only in sets of two independent
experiments due to low cell growth. To assess whether the
eﬀect of viscumTT was synergistic, Webb’s fractional product
(∗Fp) [48] was calculated as described before [42]. Values
greater than one (∗Fp> 1) display a synergistic eﬀect. Two-
way ANOVA and Bonferroni post hoc tests were applied to
determine diﬀerences between mouse xenograft treatment
groups. All results with p ≤ 0 05 were considered signiﬁcant.
3. Results
3.1. viscumTT Inhibits Cell Proliferation and Induces
Apoptosis Synergistically In Vitro. To assess the antiprolifera-
tive eﬀects of mistletoe extracts, RMS-13 and RH-30 cells
were incubated with increasing concentrations of viscum,
TT, and viscumTT. Both, viscum and viscumTT, eﬀectively
inhibited proliferation in a dose-dependent manner in
3Journal of Immunology Research
RMS-13 cells, whereas TT showed only moderate inhibitory
eﬀects (Figure 1(a)). RH-30 cells were more resistant towards
treatment with viscum or TT, while viscumTT showed a
strong inhibitory eﬀect. Notably, treatment with viscumTT
led to a synergistic inhibitory eﬀect on cell proliferation in
both cell lines in higher concentrations (∗Fp> 1).
To determine the induction of apoptosis, RMS-13
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Figure 1: viscumTT inhibits cell proliferation and induces apoptosis synergistically in ARMS. (a) RMS-13 and RH-30 cells were incubated
with viscum, TT, and viscumTT in increasing concentrations for 24 h. Cell proliferation was measured by CASY cell counter analysis, and
the proliferation rate was calculated from the total cell numbers compared to untreated control cells. Apoptosis was assessed by annexin
V/PI assay, and results were analysed by FlowJo Software. (b) RMS-13 cells were treated with viscum, TT, and viscumTT in increasing
concentrations, and early cytotoxicity was measured by LDH assay. Results are presented as percentage of untreated control cells.
(c) Apoptosis was conﬁrmed by PARP cleavage. For this purpose, Western blot analyses were performed after treatment of RMS-13 cells
with viscum, TT, and viscumTT. β-actin served as a loading control. Results are presented as means± SD of three independent
experiments. Webb’s fractional product (Fp) was calculated to assess synergism, values ∗Fp> 1 display synergism. Mistletoe lectin (ML)
and oleanolic acid (OA) concentrations were used as marker substances for viscum and TT, respectively.
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and FACS analysis after 24 h of incubation with viscum,
TT, and viscumTT. Neither viscum nor TT aﬀected apo-
ptosis in RH-30 cells; however, viscumTT induced apo-
ptosis at high concentration ranges (Figure 1(a)). In
comparison, RMS-13 cells reacted more sensitively to
incubation with viscum and viscumTT, but treatment with
TT also proved to be ineﬀective. viscumTT again dis-
















































































































































Figure 2: viscumTT displays synergistic eﬀects on mitochondrial membrane (ΔΨm) depolarisation and activation of CASP3, CASP8, and
CASP9. RMS-13 cells were incubated with viscum, TT, and viscumTT in increasing concentrations for 24 h. (a) ΔΨm depolarisation was
analysed by JC-1 staining and ﬂow cytometry. The protonophore carbonyl cyanide 3-chlorophenylhydrazone (CCCP), a mitochondrial
membrane disruptor, was used as a positive control. (b) Active caspase assays were performed according to the manufacturer’s
instructions to monitor activation of caspase-3 (CASP3), caspase-8 (CASP8), and caspase-9 (CASP9). All results are presented as
means± SD of three independent experiments. Webb’s fractional product (Fp) was calculated to assess synergism, values ∗Fp> 1 display

















































Figure 3: Caspase inhibitors eﬀectively reduce viscum- and viscumTT-mediated apoptosis. RMS-13 cells were pretreated with 50–100 μmol of
caspase inhibitors Z-VAD-FMK (pan inhibitor), Z-IETD-FMK (caspase-8), Z-LEHD-FMK (caspase-9), or Z-AEVD-FMK (caspase-10) for
one hour. Subsequently, cells were treated with viscum, TT, and viscumTT for 24 h and analysed by annexin/PI assay and ﬂow cytometry.
Results are presented as percentage of untreated control cells and means± SD of three independent experiments. Mistletoe lectin (ML)
and oleanolic acid (OA) concentrations were used as marker substances for viscum and TT, respectively.
5Journal of Immunology Research
cell lines at high concentration ranges. Detection of PARP
cleavage by Western blot analysis conﬁrmed apoptosis
induction (Figure 1(c)).
To exclude an unwanted early cytotoxic eﬀect via necro-
sis, LDH-release was measured after 2 h of incubation with
viscum, TT, and viscumTT in RMS-13 cells. As shown in
Figure 1(b), no signiﬁcant LDH-release was detected; hence,
a cytotoxic eﬀect by necrosis could be excluded.
3.2. viscumTT Displays a Synergistic Eﬀect on Mitochondrial
Membrane Depolarisation and Caspase Activation In Vitro.
To evaluate the underlying mechanisms of viscum-, TT-,
and viscumTT-induced cytotoxicity more closely, we ana-
lysed the involvement of mitochondria and caspases in
apoptosis. For this purpose, RMS-13 cells were treated as
described above and ΔΨm loss was detected by JC-1 staining
and FACS analysis. Treatment with viscum, and to an even
more pronounced extent with viscumTT, led to a dose-
dependent loss of ΔΨm, whereas TT showed no signiﬁcant
eﬀect (Figure 2(a)).
Caspases play an essential role in apoptosis, since they are
initiators (CASP9, CASP8) as well as eﬀectors (CASP3).
After 24 h treatment with viscum, TT, and viscumTT, caspase
activation was assessed by active caspase assays and FACS
analysis in RMS-13 cells. Viscum as well as viscumTT acti-
vated CASP3, CASP8, and CASP9 in a dose-dependent
manner (Figure 2(b)). viscumTT displayed a synergistic
eﬀect on mitochondrial membrane depolarisation and cas-
pase activation, conﬁrming observations made in the pre-
vious experiments.
To further determine caspase dependency in apoptosis
induction, caspase inhibitor assays were performed and inhi-
bition of apoptosis was estimated from untreated control
cells. Interestingly, caspase inhibitors were more eﬀective in
preventing apoptosis in cells treated with viscum rather than
viscumTT. The pan-caspase inhibitor achieved reduction of
apoptosis by up to 73% in viscum- and 46% in viscumTT-
treated cells (Figure 3). Inhibition of the extrinsic pathway
by CASP10 and CASP8 inhibitors prevented apoptosis by
up to 75% and 60%, respectively, after treatment with viscum
and by 50% and 30%, respectively, in viscumTT-treated cells.
Inhibition of the intrinsic apoptosis signalling pathway by
CASP9 inhibitor was also eﬀective in viscum-treated cells,
but showed no eﬀect after incubation with viscumTT. On
the contrary, in increasing concentrations, CASP9 inhibitor
enhanced viscumTT-induced apoptosis.
These results suggest that in addition to the intrinsic sig-
nalling pathway the extrinsic pathway plays a role in viscum
and viscumTT-induced caspase-dependent apoptosis.
3.3. Viscum album Extracts Alter the Expression of
Antiapoptotic Proteins. To further elucidate the underlying
molecular mechanisms of viscum-, TT-, and viscumTT-
induced apoptosis, we analysed protein expression of
apoptosis-associated proteins by Western blot analysis after
24 h treatment with mistletoe extracts. Viscum, TT, and
viscumTT suppressed the expression of the inhibitor of
apoptosis protein (IAP) family members XIAP and BIRC5.
Further, incubation with viscum and viscumTT led to
downregulation of BCL2 family members BCL2, BCL2L1,
and MCL1 (Figure 4).
3.4. viscumTT Inhibits Proliferation and Induces Apoptosis Ex
Vivo. To verify in vitro results, we next examined the eﬀects
of viscum, TT, and viscumTT in primary RMS tumour cells
(ex vivo). For this purpose, ex vivo cultures of primary cells
of three diﬀerent patients were treated with TT, viscum, and
viscumTT in increasing concentrations for 48 h (patient no.
1) and 24h (patient no. 2; patient no. 3), respectively.
Patient no. 1 was incubated with lower concentrations of
viscum, TT, and viscumTT than patient no. 2 and patient no.
3, but we changed the time course and extended the incuba-
tion time to 48 h. Viscum and to a more pronounced extent
viscumTT eﬀectively induced apoptosis and decreased ΔΨm,
while TT showed no cytotoxic eﬀect ex vivo (Figure 5(a)).
Patient no. 2 showed only a moderate increase of apoptotic
cells after treatment with viscumTT, while neither TT nor
viscum inhibited cell proliferation or induced apoptosis
eﬀectively after 24 h incubation (Figure 5(b)). After 24h
incubation with viscum and viscumTT, we were able to detect
a concentration-dependent inhibition of proliferation as well
as induction of apoptosis in patient no. 3 (Figure 5(c)).
3.5. viscumTT Eﬀectively Inhibits Tumour Growth In Vivo.




































Figure 4: viscumTT alters the expression of antiapoptotic proteins.
RMS-13 cells were treated with viscum, TT, and viscumTT in
increasing concentrations for 24 h. Afterwards, cells were lysed
and whole proteins lysates were analysed by Western blot for
altered expression of X-linked inhibitor of apoptosis protein
(XIAP), baculoviral IAP repeat containing 5 (BIRC5), myeloid cell
leukemia 1 (MCL1), B-cell lymphoma 2 (BCL2), and BCL2 like 1
(BCL2L1). β-actin served as a loading control. Mistletoe lectin
(ML) and oleanolic acid (OA) concentrations were used as marker
substances for viscum and TT, respectively.
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two patient-derived xenografts (PDX) to examine the eﬀects
of viscum, TT, and viscumTT in vivo. For this purpose, we
focused on two diﬀerent study designs. In PDX no. 1, we
examined the therapeutic eﬀect of i.t.-administered vis-
cumTT compared to viscum, TT, and doxorubicin. In PDX
no. 2, however, we investigated the therapeutic eﬀectiveness
of i.t. and i.v. application. Therefore, NMRI-nu/nu mice were
treated with viscum, TT, and viscumTT (i.v. and/or i.t.). Con-
trol groups received the vehicle cyclodextrin i.v. or i.t.
Extracts were administered every two to three days in
increasing concentrations, and each concentration was given
twice. During treatment, the mice showed no signiﬁcant loss
of body weight, and the administered extracts were well toler-
ated. The mean tumour volumes were calculated (Figure 6).
In PDX no. 1, i.t. administration of viscum and TT reduced
tumour volume eﬀectively and viscumTT led to a signiﬁcant
inhibition of tumour volume in comparison to the control
group (Figure 6(a)), whereas doxorubicin as a standard ther-
apeutic drug had no eﬀect. In PDX no. 2, viscumTT i.t. was
more eﬀective than viscumTT i.v. and both application forms
inhibited tumour volume signiﬁcantly compared to control
mice (Figure 6(b)).
4. Discussion
This study shows that viscum and viscumTT exerted strong
antiproliferative and apoptosis-inducing eﬀects on RMS
in vitro and ex vivo, whereas TT showed only moderate
inhibitory eﬀects. RH-30 cells were more resistant to viscum
treatment than RMS-13 cells. It is known that cytotoxic
eﬀects of ML, the main component of the viscum extract, dif-
fer in cell lines, probably due to diﬀerences in expression of
ML binding sites on the cell surface [49, 50]. The marker sub-
stance of the TT extract OA, which exert cytotoxic eﬀects in
various cancer cell lines [37, 46, 51], did not induce apoptosis
in either RMS cell line eﬀectively, which might be due to low
OA concentrations. The whole mistletoe extract, viscumTT,
proved to be more potent than the single extracts and dis-
played a synergistic eﬀect on apoptosis induction in RMS
cells in vitro and ex vivo. This result is in line with the
assumption that whole plant extracts can be more eﬀective
than their single constituents [52–54]. Synergistic eﬀects of
viscumTT were already recently shown in other paediatric
tumour cell lines [41–44].
Viscum and viscumTT triggered apoptosis in RMS via the
extrinsic as well as the intrinsic apoptosis signalling pathway,
evidenced by mitochondrial membrane depolarisation and
activation of CASP8 and CASP9 (Figure 7). This is in line
with results from several studies, which reported that ML as
well as OA induced apoptosis by aﬀecting diﬀerent apoptosis
pathways. Aqueous mistletoe extracts as well as puriﬁed ML
proved to exert cytotoxic eﬀects in various cancer cell lines
either by the intrinsic [21, 25, 55] or additionally by the
extrinsic [41, 56] apoptosis signalling pathway. OA and
its derivatives are also known to invoke both the extrinsic
[57–62] as well as the intrinsic [37–39] signalling pathway.
Furthermore, BA could induce apoptosis via the mitochon-
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Figure 5: viscumTT induces apoptosis synergistically ex vivo. Ex vivo cultures from three diﬀerent patients were incubated with viscum, TT,
and viscumTT in increasing concentrations for 48 h (a) patient no. 1 or for 24 h, (b) patient no. 2, and (c) patient no. 3. Cell proliferation was
measured by CASY cell counter analysis, and apoptosis was assessed by annexin V/PI assay and ﬂow cytometry. All results are presented as
means± SD of two independent experiments. Webb’s fractional product (∗Fp) was calculated to assess synergism, values ∗Fp> 1 display
synergism. Mistletoe lectin (ML) and oleanolic acid (OA) concentrations were used as marker substances for viscum and TT, respectively.
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[64]. Additionally, BA and OA have been shown to interact
directly with mitochondrial membranes [64–66].
Caspase inhibitory assays showed that viscum- and
viscumTT-induced apoptosis was caspase-dependent. Inter-
estingly, caspase inhibitors were more eﬀective in preventing
apoptosis in cells treated with viscum rather than viscumTT.
Addition of triterpene acids to aqueous mistletoe extracts
seems to activate as yet unknown mechanisms, which
enhance apoptosis induction caspase independently.
Caspase-independent apoptosis induction by OA was also
observed by Konopleva et al. [66].
Inhibition of the extrinsic pathway by CASP8 and
CASP10 inhibitors reduced apoptosis signiﬁcantly. Nota-
bly, the CASP10 inhibitor was more eﬀective in reducing
apoptosis than the pan-caspase inhibitor, underlining the
dependency of viscum- and viscumTT-mediated apoptosis
induction on CASP10. CASP10 is a homologue of CASP8
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Figure 6: viscumTT eﬀectively reduces tumour volume in patient-derived RMS xenografts. Patient-derived RMS cells from (a) patient no. 1
and (b) patient no. 2 were used for s.c. implantation in the inguinal region of mice. Treatment started on day 12 when tumours were palpable,
with (a) i.t. administration of viscum, TT, viscumTT, cyclodextrins (CD; control group), and i.v. doxorubicin (Doxo) and (b) i.t.
administration of viscumTT and i.v. treatment with viscumTT and cyclodextrins. The mice were treated every two-three days in rising
concentrations, and each dose was given twice. The administered concentrations were 40/60/80mg/kg oleanolic acid (TT), 0.5/1.0/1.5 μg/
kg mistletoe lectin (viscum), or a combination thereof (viscumTT). Two-way ANOVA and Bonferroni post hoc tests were applied to
determine diﬀerences between mouse xenograft treatment groups (∗∗p ≤ 0 01).
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However, some studies indicate involvement of CASP10 in
apoptosis induction by cytotoxic agents in a FADD-
dependent but receptor-independent manner [67, 68].
Interestingly, the CASP9 inhibitor was not only
ineﬀective in viscumTT-treated cells, but enhanced vis-
cumTT-induced cell death. This result is in line with the
previous results, which reported augmented apoptosis after
treatment with inhibitors of CASP9 in combination with
oridonin [69]. Also, CASP9 inhibition is suspected to
block autophagic ﬂux and thus to promote caspase-
independent cell death [69, 70]. However, caspase inhibi-
tor assays suggest that CASP9 does not act as an initiator
but merely as an eﬀector caspase in an ampliﬁcation loop
and is activated by CASP8 or CASP10 similar to TNF-α,
which induced apoptosis via activation of CASP9 by
CASP8 [71, 72]. Additionally, the mitochondrial and
receptor-mediated pathways are crosslinked by the cleavage
of BH3 interacting domain death agonist (BID) into trun-
cated BID (tBID) by CASP8 or CASP10. Also, cotreatment




























Figure 7: Scheme for viscumTT-induced apoptosis via the extrinsic and the intrinsic signalling pathways. Through yet unknown
mechanisms, viscumTT activates caspase-8 (CASP8) and caspase-10 (CASP10), resulting in an activation of the caspase cascade. Caspase-9
(CASP9) acts as an eﬀector downstream of CASP8 and CASP10 rather than an initiator of apoptosis. Further, viscumTT downregulates
antiapoptotic proteins B-cell lymphoma 2 (BCL2), BCL2 like 1 (BCL2L1), and myeloid cell leukemia 1 (MCL1) as well as inhibitors of
apoptosis proteins baculoviral IAP repeat containing 5 (BIRC5) and X-linked inhibitor of apoptosis protein (XIAP), thus shifting the
balance towards apoptosis.
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dioxoolean-1,9-dien-28-oic acid (CDDO-Me) and CASP8
inhibitor CASP9 activity was decreased, suggesting that
CASP9 activation is downstream of CASP8 [73].
To illuminate the underlying mechanisms of viscum-,
TT-, and viscumTT-induced apoptosis further, apoptosis-
associated proteins were analysed by Western blot analyses
to detect altered expression. The results showed that viscum
and even more prominently viscumTT shifted the balance
towards apoptosis by changing the ratio of pro- and antia-
poptotic proteins.
After treatment with viscum and viscumTT, downregula-
tion of the antiapoptotic BCL2 family members BCL2 and
BCL2L1 was detected. Overexpression of BCL2 family mem-
bers is often found in cancers and contributes to apoptosis
resistance. Genetic mutations, for example, gli-ampliﬁcation
and a positive PAX3/FOXO1 fusion status, and increased
activity of transcription factor signal transducer and activator
of transcription 3 (STAT3) lead to overexpression of BCL2
and BCL2L1 in RMS [74]. Downregulation of BCL2 and
BCL2L1 was found after treatment with viscum [42] and
OA [75, 76]. MCL1, another antiapoptotic BCL2 family
member, which is upregulated in RMS [77], is also down-
regulated by viscum and viscumTT. This is in line with the
previous results of decreased expression of MCL1 after
treatment with ML [21, 78] and viscumTT [43]. Further-
more, Ryu et al. have shown inhibition of the STAT3
pathway with downregulation of BCL2L1, BIRC5, and
MCL1 after incubation with CDDO-Me [79]. Moreover,
viscum and viscumTT eﬀectively reduced expression of
IAP family members BIRC5 and XIAP. IAP family members
prevent apoptosis by directly inhibiting caspases or the
assembly of proapoptotic complexes. BIRC5 is often highly
expressed in malignant cells but not in diﬀerentiated tissues
[80], and high expression levels are associated with poor
prognosis [81] thus appointing it an attractive target in
tumour therapy. RMS expresses high levels of BIRC5, and
Caldas et al. were able to eﬀectively reduce tumour growth
by blocking BIRC5 in vivo [82]. OA treatment was able to
eﬀectively reduce BIRC5 expression in lung cancer [83],
ovarian cell carcinoma [75, 84], and leukaemia [76] as well
as XIAP expression in hepatocellular carcinoma [85].
Furthermore, we were able to show that viscum, TT, and
viscumTT led to downregulation of BIRC5 and XIAP in
AML [41], Ewing-sarcoma [43], and osteosarcoma [44].
Treatment with viscumTT seems to be more eﬀective
compared to the single compounds ex vivo and in vivo. Fur-
thermore, viscumTT was more eﬀective in reducing tumour
volume than i.v. doxorubicin treatment in PDX no. 1. In
addition, comparison of i.v. and i.t. treatment (PDX no. 2)
showed that i.t. treatment is more eﬀective. On the other
hand, viscumTT can be administered in higher concentra-
tions i.v. than i.t. Notably, viscumTT was more eﬀective
in vivo than in vitro. While viscumTT showed only moderate
apoptosis-inducing properties ex vivo, tumour volume was
eﬀectively reduced in the xenograft derived from the same
patient. Since mistletoe extracts are metabolised by mice,
these in vitro results cannot be directly extrapolated to
in vivo settings. However, viscumTT shows promising
antitumour activity in ARMS.
5. Conclusions
The results show the high potential of viscumTT to induce
apoptosis in ARMS without limiting toxicity. viscumTT is
more eﬀective than the single compounds and leads to a
synergistic eﬀect on apoptosis induction in vitro as well as
ex vivo. In vivo viscumTT treatment resulted in an eﬀective
reduction of tumour volume compared to controls. In
conclusion, addition of triterpene acids to aqueous mistletoe
extracts enhances their cytotoxic eﬀects in ARMS through an
as yet unknown mechanism. However, viscumTT is a
promising novel treatment approach for ARMS. Further-
more, ML exerts immunomodulating eﬀects [86, 87]. The
antiproliferative and apoptosis-inducing properties of
viscumTT combined with the immunomodulating actions
of ML provide an attractive research target not only for
cancer therapy, but also for other research purposes such
as rheumatic and cardiovascular diseases.
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